First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis with 3-year follow-up.

被引：0
|
作者：
Shen, Lin
Bai, Yuxian
Lin, Xiaoyan
Li, Wei
Wang, Jufeng
Zhang, Xiaochun
Pan, Hongming
Bai, Chunmei
Bai, Li
Cheng, Ying
Zhang, Jingdong
Zhong, Haijun
Ba, Yi
Hu, Wenwei
Xu, Rui-Hua
Guo, Weijian
Qin, Shukui
Wang, Rui
Sullivan, Kendall
Liu, Tianshu
机构：
[1] Peking Univ Canc Hosp & Inst, Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[2] Herbin Med Univ, Harbin, Heilongjiang, Peoples R China
[3] Fujian Med Univ Union Hosp, Fuzhou, Peoples R China
[4] First Hosp Jilin Univ, Changchun, Peoples R China
[5] Henan Canc Hosp, Zhengzhou, Peoples R China
[6] Qingdao Univ, Affiliated Hosp, Qingdao, Peoples R China
[7] Sir Run Run Shaw Hosp, Hangzhou, Peoples R China
[8] Peking Union Med Coll Hosp, Dept Oncol, Beijing, Peoples R China
[9] China PLA Gen Hosp 301 Hosp, Beijing, Peoples R China
[10] Jilin Canc Hosp, Changchun, Peoples R China
[11] Liaoning Canc Hosp & Inst, Shenyang, Peoples R China
[12] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[13] Tianjin Med Univ Canc Inst & Hosp, Tianjin, Peoples R China
[14] First Peoples Hosp Changzhou, Changzhou, Jiangsu, Peoples R China
[15] Sun Yat Sen Univ, Med Oncol Canc Ctr, Guangzhou, Peoples R China
[16] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[17] Eastern Theater Gen Hosp, Qinhuai Dist Med Area, Nanjing, Jiangsu, Peoples R China
[18] Bristol Myers Squibb, Princeton, NJ USA
[19] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
353
引用
收藏
页码：353 / 353
页数：1
相关论文
共 50 条
  • [1] First-Line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis.
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Ruihua
    Guo, Weijian
    Qin, Shukui
    Yang, Nong
    Lu, Jianwei
    Shitara, Kohei
    Lei, Ming
    Li, Mingshun
    Bao, Nicole
    Chen, Tian
    Liu, Tianshu
    CANCER RESEARCH, 2021, 81 (13)
  • [2] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
    Moehler, M.
    Janjigian, Y. Y.
    Shitara, K.
    Garrido, M.
    Gallardo, C.
    Shen, L.
    Yamaguchi, K.
    Wyrwicz, L.
    Skoczylas, T.
    Bragagnoli, A.
    Liu, T.
    Tehfe, M.
    Elimova, E.
    Bruges, R.
    Cleary, J. M.
    Karamouzis, M.
    Soleymani, S.
    Lei, M.
    Amaya, Chanaga C.
    Ajani, J. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 114 - 115
  • [3] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649
    Janjigian, Yelena Y.
    Shitara, Kohei
    Moehler, Markus H.
    Garrido, Marcelo
    Gallardo, Carlos
    Shen, Lin
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Bragagnoli, Arinilda Silva Campos
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Maya, Ricardo Elias Bruges
    Cleary, James M.
    Karamouzis, Michalis
    Soleymani, Samira
    Lei, Ming
    Amaya-Chanaga, Carlos
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [4] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Rui-Hua
    Guo, Weijian
    Qin, Shukui
    Wang, Rui
    McCraith, Stephen
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 318 - 318
  • [5] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649.
    Janjigian, Yelena Y.
    Shitara, Kohei
    Moehler, Markus H.
    Garrido, Marcelo
    Gallardo, Carlos
    Shen, Lin
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Bragagnoli, Arinilda Silva Campos
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Maya, Ricardo Elias Bruges
    Cleary, James M.
    Karamouzis, Michalis
    Soleymani, Samira
    Lei, Ming
    Amaya-Chanaga, Carlos
    Ajani, Jaffer A.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 291 - 291
  • [6] First-line nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients with advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 2-year follow-up
    Shen, L.
    Bai, Y.
    Lin, X.
    Li, W.
    Wang, J.
    Zhang, X.
    Pan, H.
    Bai, C.
    Bai, L.
    Cheng, Y.
    Zhang, J.
    Zhong, H.
    Ba, Y.
    Hu, W.
    Xu, R.
    Guo, W.
    Qin, S.
    Yang, N.
    Lu, J.
    Chanaga, C. Amaya
    Soleymani, S.
    Liu, T.
    ANNALS OF ONCOLOGY, 2022, 33 : S279 - S279
  • [7] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate
    Moehler, Markus
    Janjigian, Yelena Y.
    Shitara, Kohei
    Garrido, Marcelo
    Gallardo, Carlos
    Shen, Lin
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Bruges, Ricardo
    Cleary, James M.
    Karamouzis, Michalis
    Soleymani, Samira
    Lei, Ming
    Chanaga, Carlos Amaya
    Ajani, Jaffer A.
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 64 - 64
  • [8] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 biomarker analyses
    Lei, Ming
    Janjigian, Yelena Y.
    Ajani, Jaffer A.
    Moehler, Markus
    Wang, Xuya
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Yamaguchi, Kensei
    Wyrwicz, Lucjan
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Elimova, Elena
    Li, Mingshun
    Poulart, Valerie
    Wang, Yu
    Doshi, Parul
    Shitara., Kohei
    CANCER RESEARCH, 2022, 82 (12)
  • [9] Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649
    Elimova, Elena
    Shitara, Kohei
    Moehler, Markus H.
    Ajani, Jaffer A.
    Shen, Lin
    Garrido, Marcelo
    Gallardo, Carlos
    Wyrwicz, Lucjan S.
    Yamaguchi, Kensei
    Cleary, James M.
    Maya, Ricardo Elias Bruges
    Karamouzis, Michalis
    Skoczylas, Tomasz
    Bragagnoli, Arinilda
    Liu, Tianshu
    Tehfe, Mustapha
    Feeney, Kynan
    Wang, Rui
    Nathani, Raheel
    Janjigian, Yelena Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.
    Shen, Lin
    Bai, Yuxian
    Lin, Xiaoyan
    Li, Wei
    Wang, Jufeng
    Zhang, Xiaochun
    Pan, Hongming
    Bai, Chunmei
    Bai, Li
    Cheng, Ying
    Zhang, Jingdong
    Zhong, Haijun
    Ba, Yi
    Hu, Wenwei
    Xu, Rui-Hua
    Guo, Weijian
    Qin, Shukui
    Hu, Nan
    McCraith, Stephen
    Liu, Tianshu
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 392 - 392
12345